Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 13/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245596 | 0.83 | RAF1 (0.68) | RAF1MAPK14 | |
| SCHEMBL3226707 | 0.80 | MAPK14 (1.00) | RAF1MAPK14 | |
| SCHEMBL3241657 | 0.79 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3226722 | 0.75 | RAF1 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3237625 | 0.75 | MAPK14 (1.00) | RAF1MAPK14 | |
| SCHEMBL3242693 | 0.75 | MAPK14 (1.00) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4424145 | 0.69 | MAPK14 (0.43) | RAF1MAPK14 | |
| SCHEMBL3217612 | 0.66 | MAPK14 (0.52) | RAF1MAPK14 | |
| SCHEMBL10308265 | 0.64 | MAPK14 (0.50) | RAF1MAPK14 | |
| SCHEMBL668770 | 0.64 | RAB9A (0.60) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | claimed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | claimed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | claimed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | RAF1 237/4885MAPK14 40/4885MAPK13 39/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | RAF1 237/4885MAPK14 40/4885MAPK13 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.